Activity

Meeting with Corewell Health Karen Bolhuis September 11, 2025 • 29 mins • View Meeting ACTION ITEMS ✨ Upgrade to Premium to unlock AI generated action items MEETING SUMMARY ✨ Chronological Template Upgrade to Premium to revert to advanced summary templates Corewell Health's acquisition by Quest @ 0:58 Corewell Health has entered into a joint venture agreement with Quest Diagnostics, where Quest will be the majority 51% stakeholder and Corewell will be the 49% minority partner. This transition is expected to take effect on January 1st, 2027, at which point Corewell employees will become Quest employees. The east side of the state will be the first to transition their ordering and operations to the new Quest system, while the west side (where Corewell Health is located) will follow a few months later in Q2 2027. Impact on testing methods and QC ordering @ 3:32 For the first year of the transition (2027), Corewell's existing lab operations and test methods will remain the same. However, all ordering will go through Quest rather than directly through Corewell. The new joint venture lab being built in Southfield, MI will handle outpatient, non-time-sensitive testing, while the existing Corewell hospital labs will continue operating under Corewell policies. There is uncertainty around potential future changes to test methods and QC ordering processes. Transition planning and next steps @ 5:53 With the uncertainty around the Corewell-Quest transition, Corewell is focused on maintaining their current operations and does not have capacity to assist with any new product development or testing at this time. UTAK agreed to stay in close contact to ensure a smooth transition, including potentially placing a larger order before year-end to avoid any supply disruptions. Corewell will provide UTAK with contact information for the Quest team member leading the east side transition, so UTAK can coordinate with them as well. UTAK's custom QC products and performance @ 7:05 Corewell heavily utilizes UTAK's custom QC products, which help streamline their workflow by allowing them to run fewer QCs per batch. They have been generally satisfied with UTAK's products and service, though have occasionally seen some clumping issues with whole blood QCs a few days after reconstitution. UTAK agreed to look into this issue further. Corewell is planning to place an order for a custom PETH QC that they are currently validating. View Meeting →